Macrophage migration inhibitory factor promotes intestinal tumorigenesis.

BACKGROUND & AIMS The cytokine macrophage migration inhibitory factor (MIF) is expressed throughout the human gastrointestinal tract. Recently, protumorigenic activity of MIF has been described in several cancer models. Therefore, we investigated the expression and function of MIF during the early stages of intestinal tumorigenesis. METHODS MIF messenger RNA, protein, and tautomerase activity were measured in normal intestinal mucosa and adenomas from patients with sporadic colorectal adenomas and in the adenomatous polyposis coli (Apc)Min/+ mouse model of intestinal tumorigenesis. MIF function was investigated by using VACO-235 human colorectal adenoma cells in vitro and by testing the effect of genetic deletion of Mif on ApcMin/+ mouse intestinal tumorigenesis. RESULTS MIF expression and tautomerase activity were increased in human and ApcMin/+ mouse intestinal adenomas compared with adjacent normal mucosa. Up-regulation of MIF occurred mainly in epithelial cells (associated with an increasing grade of dysplasia), but also in stromal plasma cells. Exogenous MIF inhibited apoptosis and promoted anchorage-independent growth of VACO-235 cells (maximal at 100 ng/mL). Homozygous deletion of Mif was associated with a reduction in the number and size of ApcMin/+ mouse adenomas (P = .025 for the difference in large [>7-mm] tumors) and decreased angiogenesis (43% decrease in mean tumor microvessel density), but there was no alteration in epithelial cell apoptosis or proliferation. CONCLUSIONS MIF expression is increased in sporadic human colorectal adenomas, and exogenous MIF drives tumorigenic behavior of epithelial cells in vitro. Mif also promotes intestinal tumorigenesis (predominantly via angiogenesis) in the ApcMin/+ mouse. Therefore, MIF is a potential colorectal cancer chemoprevention target.

[1]  S. Narumiya,et al.  Cyclooxygenase 2- and prostaglandin E2 receptor EP2-dependent angiogenesis in ApcΔ716 mouse intestinal polyps , 2002 .

[2]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[3]  R. Bucala,et al.  Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. , 2002, Journal of medicinal chemistry.

[4]  R. Bucala,et al.  Macrophage migration inhibitory factor. , 2005, Critical care medicine.

[5]  E. Lander,et al.  Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Myeroff,et al.  A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene. , 1994, The Journal of clinical investigation.

[7]  N. Funata,et al.  Expression of Macrophage Migration Inhibitory Factor in Human Breast Cancer: Association with Nodal Spread , 2002, Japanese journal of cancer research : Gann.

[8]  M. Suzuki,et al.  High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. , 1999, Biochemical and biophysical research communications.

[9]  Elias Lolis,et al.  The Tautomerase Active Site of Macrophage Migration Inhibitory Factor Is a Potential Target for Discovery of Novel Anti-inflammatory Agents* , 2002, The Journal of Biological Chemistry.

[10]  V. Paralkar,et al.  Cloning the human gene for macrophage migration inhibitory factor (MIF). , 1994, Genomics.

[11]  O. Volpert,et al.  Migration Inhibitory Factor Mediates Angiogenesis via Mitogen-Activated Protein Kinase and Phosphatidylinositol Kinase , 2003, Circulation research.

[12]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[13]  Yuji Sato,et al.  Macrophage Migration Inhibitory Factor (MIF) , 1996 .

[14]  O. Petrenko,et al.  The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Campos-Caro,et al.  Isolation, maturational level, and functional capacity of human colon lamina propria plasma cells , 2003, Gut.

[16]  T. Iwanaga,et al.  Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. , 2002, Gastroenterology.

[17]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[18]  Carlos Cordon-Cardo,et al.  At the Crossroads of Inflammation and Tumorigenesis , 1999, The Journal of experimental medicine.

[19]  E. Gaffney,et al.  Morphologically distinct patterns of apoptosis correlate with size and high‐grade dysplasia in colonic adenomas , 2004, Histopathology.

[20]  N. Perkins,et al.  Transcriptional Cross Talk between NF-κB and p53 , 1999, Molecular and Cellular Biology.

[21]  R. Bucala,et al.  An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma , 1999, Molecular medicine.

[22]  J. Willson,et al.  Cell culture of human colon adenomas and carcinomas. , 1987, Cancer research.

[23]  E Lolis,et al.  Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. , 1999, Biochemistry.

[24]  T. Shkolnik,et al.  The macrophage migration inhibition (MIF) assay as a marker of colorectal cancer , 1987, Diseases of the colon and rectum.

[25]  G. Hannon,et al.  A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.

[26]  G. Fingerle-Rowson,et al.  Macrophage Migration Inhibitory Factor Deficiency Is Associated with Altered Cell Growth and Reduced Susceptibility to Ras-mediated Transformation* , 2003, The Journal of Biological Chemistry.

[27]  T. Shkolnik,et al.  Colon cancer bearing rats produce a lymphokine which induces macrophage migration inhibition (MIF) in vitro. , 1988, Comparative immunology, microbiology and infectious diseases.

[28]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[29]  A. Markham,et al.  Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells , 2002, Oncogene.

[30]  K. Kovacs,et al.  Immunocytochemical localization of macrophage migration inhibitory factor in human hypophysis and pituitary adenomas. , 1997, Archives of pathology & laboratory medicine.

[31]  L. Coussens,et al.  Soluble mediators of inflammation during tumor development. , 2005, Advances in cancer research.

[32]  H. Dosaka-akita,et al.  Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung , 2000, Cancer.

[33]  E. Rosengren,et al.  Isolation of a new tautomerase monitored by the conversion of D-dopachrome to 5,6-dihydroxyindole. , 1993, Biochemical and biophysical research communications.

[34]  A. Satoskar,et al.  Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis , 1999, The Journal of experimental medicine.

[35]  S. Deventer,et al.  Development of chronic colitis is dependent on the cytokine MIF , 2001, Nature Immunology.

[36]  Robert Kiss,et al.  Prognostic Values of Galectin-3 and the Macrophage Migration Inhibitory Factor (MIF) in Human Colorectal Cancers , 2003, Modern Pathology.

[37]  M. Symons,et al.  Rho GTPase-dependent Signaling Is Required for Macrophage Migration Inhibitory Factor-mediated Expression of Cyclin D1* , 2005, Journal of Biological Chemistry.

[38]  R. Mitchell.  Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. , 2004, Cellular signalling.

[39]  M. Kagnoff,et al.  Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. , 2002, Gastroenterology.

[40]  R. Poulsom,et al.  Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. , 2001, Gastroenterology.

[41]  C. Akdis,et al.  Human B cells secrete migration inhibition factor (MIF) and present a naturally processed MIF peptide on HLA‐DRB1*0405 by a FXXL motif , 1999, Immunology.

[42]  J. Woodgett,et al.  A molecular compendium of genes expressed in multiple myeloma. , 2002, Blood.

[43]  M. Onji,et al.  Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance , 2001, European journal of clinical investigation.

[44]  Y. Hishikawa,et al.  Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma , 2005, Cancer.

[45]  K. Washington,et al.  Pathology of mouse models of intestinal cancer: consensus report and recommendations. , 2003, Gastroenterology.

[46]  Yuji Sato,et al.  Induction of macrophage migration inhibitory factor by lysophosphatidic acid: relevance to tumor growth and angiogenesis. , 2003, International journal of molecular medicine.

[47]  M. Iannettoni,et al.  Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  R. Bucala.  MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid‐induced regulator of the immune response , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  J. Bernhagen,et al.  The Cytokine Macrophage Migration Inhibitory Factor Reduces Pro-Oxidative Stress-Induced Apoptosis1 , 2003, The Journal of Immunology.

[50]  J. Bernhagen,et al.  Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1 , 2000, Nature.

[51]  M. Iannettoni,et al.  Macrophage Migration Inhibitory Factor and CXC Chemokine Expression in Non-Small Cell Lung Cancer , 2003 .

[52]  Michael Bacher,et al.  Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma , 2003, International journal of cancer.

[53]  K. Goss,et al.  Biology of the adenomatous polyposis coli tumor suppressor. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Cintorino,et al.  Macrophage migration inhibitory factor in prostatic adenocarcinoma: Correlation with tumor grading and combination endocrine treatment‐related changes , 2000, The Prostate.

[55]  Tina Peng,et al.  Sustained Mitogen-activated Protein Kinase (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor (MIF) , 1999, The Journal of Biological Chemistry.

[56]  R. Bucala,et al.  Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. , 2003, Arthritis and rheumatism.